A case of cerebral venous thrombosis with intraparenchymal and subarachnoid hemorrhages was initially treated unsuccessfully with mechanical and pharmacologic thrombolysis using intrathrombus tissue plasminogen activator (tPA) and angioplasty, and later successfully treated with an intravascular ultrasound tPA infusion catheter. This new microcatheter allowed direct infusion of tPA while using local therapeutic intravascular ultrasound to increase the thrombolytic effect. Flow was quickly restored. Our patient recovered from coma to discharge home without worsening of existing hemorrhages.
Introduction
Thrombosis of dural venous sinuses represents less than 1% of strokes 1 . The time-topresentation, clinical signs and symptoms, imaging findings and outcomes are widely variable making diagnosis and treatment difficult. Heparinization is the usual treatment while focal catheter directed thrombolysis is reserved for worsening patients. Augmentation of pharmacologic thrombolysis with balloon angioplasty and rheolytic catheter thrombectomy have been reported 2 . We report a case of cerebral venous thrombosis (CVT) with intracranial hemorrhage treated with mechanical and pharmacologic thrombolysis using intrathrom-bus tissue plasminogen activator (tPA), balloon angioplasty, and an intravascular therapeutic ultrasound infusion catheter (EKOS MicroLy-sUs, EKOS Corporation; Bothell, WA, USA).
Case Report
A 41-year-old man presented to an outside hospital with a five day history of nausea and headache and two days of worsening vomiting, blurry vision, left-sided dysesthesia, and weakness. He was diagnosed with CVT and transferred to our institution. On admission, computed tomography (CT) and magnetic resonance (MR) showed diffuse subarachnoid hemorrhage and focal right basal ganglia hemorrhage with thrombosis of the superior sagittal, bilateral transverse, and left sigmoid sinuses ( Figure 1 ).
On admission the patient was awake but lethargic, oriented with intact speech, demonstrating left-sided neglect with weakness, and intact cranial nerves. A ventricular drain was placed to control elevated intracranial pressure. Due to the placement of the external ventricular drain, there was a delay in starting intravenous heparin. On hospital day two in the neuro-intensive care unit, the patient's condition deteriorated. He was intubated and started on heparin. The following day, mechanical and chemical thrombolysis using a 5mm balloon and 5 mg of intrathrombus tPA resulted in a
The microcatheter was positioned within the sagittal sinus thrombus and the clot was laced with 7.5 mg of tPA. While the ultrasound was running, the catheter was slowly withdrawn throughout the length of the clot within the sagittal sinus, torcula, and right transverse sinus over approximately thirty minutes. Flow was immediately restored from total occlusion to near complete recanalization. A stenosis within the right transverse sinus was dilated using a 6 mm balloon. Final internal carotid angiograms small improvement in flow. Over the next two days, he became comatose and continued to deteriorate with increasing intracranial pressure despite drainage and medical management. He returned to interventional radiology for ultrasound augmented thrombolysis ( Figure 2 ). The 2.5 Fr EKOS MicroLysUS catheter has a 2 mm 2.1MHz ring sonography transducer at its tip (Avg power 0.21-0.45 W) and is FDA approved for injection of contrast into the neurovasculature of humans 3 . had many of these poor prognostic and risk factors supporting more aggressive treatment.
Thrombus dynamics are multi-factorial and range from prompt autolysis to longstanding resistant thrombus that propagates in the absence of flow. In general, the effective delivery of lytic agent into the clot determines the rate of thrombolysis. In vitro and animal research has shown that ultrasound augments clot lysis by increasing drug transport, reversibly changing the fibrin structure, and increasing tPA binding affinity 6, 7 . Ultrasound reversibly changes the protein structure of the fibrin within the clot which opens more binding sites for fibrinolytic enzymes 7 . It also changes the binding kinetics of tPA to fibrin increasing the rate of clot dissolution 7 .
Enhanced thrombolysis with ultrasound has been demonstrated in human trials. The CLOT-BUST trial randomized 126 patients with middle cerebral artery thrombosis to receive intravenous tPA or intravenous tPA plus transcranial Doppler ultrasound, and showed an increased rate of recanalization in the ultrasound augmented group 6 . The Interventional Management of Stroke (IMS) II trial included patients treated with intra-arterial tPA and intraarterial localized ultrasound delivery 8 . It showed a trend toward improved revascularization using the intra-arterial ultrasound catheter compared to intra-arterial tPA alone. However, it also showed an increased number of symptomatic intracranial hemorrhages in the ultrasound catheter group 8 .
The risk of increased hemorrhage by using ultrasound was carefully weighed in this patient with existing subarachnoid and basal ganglia hemorrhage. Given his poor neurologic status and the minimal improvement from our previous attempt with tPA and angioplasty, we felt intravascular ultrasound augmentation was warranted. The EKOS catheter provides a 360° pulse wave around the distal tip with an effective range of only a few mm. Here it produced prompt recanalization with excellent flow and no hemorrhagic side effects. The nearby sites of previous hemorrhage showed no sign of increasing bleeding or other complication. The angiographic and clinical outcomes were dramatic without worsening of the existing hemorrhage. However, when considering the success of the EKOS catheter, considerations of its challenges must also be understood. The distal tip of EKOS catheter which contains the US transducer is non-flexible. This can present a showed greatly improved flow throughout the venous system (Figure 3) .
The next 24 hours brought a dramatic improvement in mental status. The coma resolved and he began to follow commands. His intracranial pressures improved. Over the next few days he was weaned from the ventricular drain and ventilator. The amount of sinus thrombosis was markedly decreased without any sign of worsening hemorrhage on repeat CT scans. At discharge home he was awake, alert, oriented, with intact speech and 4/5 left-sided weakness. He was seen in clinic six months later and MRV showed complete recanalization of the cerebral venous system.
Discussion
The diagnosis of CVT can be difficult and is often delayed by the nonspecific nature of the symptoms. Patients often initially experience headaches, nausea and vomiting. These symptoms are thought to be related to increased venous pressure. The symptoms usually progress over sub sequential days to include focal neurological deficits, seizures and decreased mentation 4 .
Traditional treatment for CVT is supportive using hydration, intravenous anticoagulation, intracranial pressure control and treatment of the underlying cause. More aggressive methods have been described including intravenous tPA, mechanical (balloon) thrombolysis, rheolytic thrombolysis, and craniectomy. No single technique has become the dominant therapeutic choice. Given the diversity of patient presentations and outcomes with CVT, it is difficult to imagine a controlled trial evaluating treatments of such a rare form of stroke.
The International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) study group published their multinational prospective observational data on 624 patients with CVT. Only 2.1% of patients were treated with catheter directed thrombolysis 5 . They reported a 30-day case fatality of 3.4% and an overall death or dependency rate of 13%. Coma, cerebral hemorrhage, and malignancy were identified as prognostic indicators of death or dependence. Increased risk of death or dependence was seen in male patients, patients over 37 years, patients with mental status disorder, thrombosis of the deep cerebral system, and central nervous system infection 5 . Our patient treatment. It deserves consideration in patients who do not respond to conventional therapy or have a high likelihood of poor outcome. It appears to be a needed and safe addition to therapeutic options, especially in difficult patients at additional risk of hemorrhage.
